HPC Offered for PRESERVE Expansion
Recruiting · NCT07145411 · Observational (researchers observe without assigning treatment) · Lead sponsor: Ossium Health, Inc.
View the official record on ClinicalTrials.gov →Interventions studied
Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)
What this trial is about
Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons. The HOPE program is expanded access program to serve these patients by providing our bone marrow product
Who can take part
Age range
12 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients aged 12-80 may be eligible\* to receive bone marrow for transplantation through the Ossium HOPE Program if:
- Their treating physician determined they are eligible for allogeneic bone marrow transplant Their treating physician determined that the potential benefit outweighs the potential risks
Where it is running
4 locations listed across 4 US states.
- University of Alabama, Birmingham - Birmingham, Alabama, United States
- Henry Ford Health - Detroit, Michigan, United States
- The Ohio State University Medical Center - Columbus, Ohio, United States
- Tristar Centennial Medical Center - Nashville, Tennessee, United States